Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13 марта 2020 г. обновлено: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Обзор исследования

Статус

Неизвестный

Вмешательство/лечение

Подробное описание

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Тип исследования

Интервенционный

Регистрация (Ожидаемый)

50

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Clermont-Ferrand, Франция, 63000
        • CHU de Clermont-Ferrand

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 12 лет до 16 лет (Ребенок)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Профилактика
  • Распределение: Нерандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Без вмешательства: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
cardiac ectopic fat deposits
Временное ограничение: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Временное ограничение: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Временное ограничение: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Временное ограничение: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Временное ограничение: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Временное ограничение: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Временное ограничение: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Временное ограничение: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Временное ограничение: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Временное ограничение: Day 0
left myocardial regional function (MRI)
Day 0

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
macrovascularisation
Временное ограничение: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Временное ограничение: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Временное ограничение: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Временное ограничение: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Временное ограничение: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Временное ограничение: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Временное ограничение: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Временное ограничение: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Временное ограничение: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Временное ограничение: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Временное ограничение: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Временное ограничение: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Временное ограничение: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Временное ограничение: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Временное ограничение: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Временное ограничение: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Временное ограничение: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Временное ограничение: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Временное ограничение: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Временное ограничение: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Временное ограничение: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Временное ограничение: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Временное ограничение: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Временное ограничение: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Временное ограничение: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Временное ограничение: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Временное ограничение: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Временное ограничение: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Временное ограничение: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Временное ограничение: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Временное ограничение: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Временное ограничение: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Временное ограничение: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Временное ограничение: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Временное ограничение: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Временное ограничение: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Временное ограничение: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Временное ограничение: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Временное ограничение: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Временное ограничение: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Временное ограничение: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Временное ограничение: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Временное ограничение: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Временное ограничение: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Временное ограничение: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Временное ограничение: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Временное ограничение: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Временное ограничение: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Временное ограничение: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Временное ограничение: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Временное ограничение: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Временное ограничение: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Временное ограничение: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Временное ограничение: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Временное ограничение: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Временное ограничение: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Временное ограничение: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Временное ограничение: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Временное ограничение: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Временное ограничение: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Временное ограничение: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Временное ограничение: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Временное ограничение: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Временное ограничение: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Временное ограничение: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Временное ограничение: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Временное ограничение: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Временное ограничение: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Временное ограничение: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Временное ограничение: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Временное ограничение: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Временное ограничение: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Временное ограничение: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Временное ограничение: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Временное ограничение: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Временное ограничение: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Временное ограничение: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Временное ограничение: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Временное ограничение: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Временное ограничение: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Временное ограничение: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Временное ограничение: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Временное ограничение: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Временное ограничение: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Временное ограничение: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Временное ограничение: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Временное ограничение: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Временное ограничение: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Временное ограничение: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Временное ограничение: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Временное ограничение: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Временное ограничение: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Временное ограничение: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Временное ограничение: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Временное ограничение: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Временное ограничение: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Временное ограничение: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Временное ограничение: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Временное ограничение: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Временное ограничение: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Временное ограничение: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Временное ограничение: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Временное ограничение: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Временное ограничение: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Временное ограничение: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Временное ограничение: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Временное ограничение: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Временное ограничение: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Временное ограничение: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Временное ограничение: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Временное ограничение: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Временное ограничение: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Временное ограничение: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Временное ограничение: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Временное ограничение: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Временное ограничение: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Временное ограничение: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Временное ограничение: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Временное ограничение: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Временное ограничение: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Временное ограничение: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Временное ограничение: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Временное ограничение: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Временное ограничение: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Временное ограничение: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Временное ограничение: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Временное ограничение: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Временное ограничение: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Временное ограничение: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Временное ограничение: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Временное ограничение: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Временное ограничение: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Временное ограничение: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Временное ограничение: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Временное ограничение: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Временное ограничение: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Временное ограничение: Day 0
measure of weight in kilograms
Day 0
weight
Временное ограничение: Month 3
measure of weight in kilograms
Month 3
waist circumference
Временное ограничение: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Временное ограничение: Month 3
measure of waist circumference in centimetres
Month 3

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Ожидаемый)

1 сентября 2020 г.

Первичное завершение (Ожидаемый)

1 июня 2021 г.

Завершение исследования (Ожидаемый)

1 июня 2021 г.

Даты регистрации исследования

Первый отправленный

10 февраля 2020 г.

Впервые представлено, что соответствует критериям контроля качества

13 марта 2020 г.

Первый опубликованный (Действительный)

17 марта 2020 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

17 марта 2020 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

13 марта 2020 г.

Последняя проверка

1 февраля 2020 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Другой идентификатор: ANSM)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

Не определился

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

продукт, произведенный в США и экспортированный из США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться